RxDoctor Payments Data

Walter Lampa, MD

Psychiatry · Lodi, CANPI 1134385354

Payments from drug & device makers

$174,020in general payments, 2019–2025

Across 502 payments — averaging $346.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$172K
  • Sunovion Pharmaceuticals Inc.$990
  • Lundbeck LLC$506
  • Otsuka America Pharmaceutical, Inc.$187
  • Alkermes, Inc.$142
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$78
  • plus $122 from 4 others

What the payments were for

  • Speaking & faculty fees$160,50092%
  • Travel & lodging$8,7115%
  • Food & beverage$4,8073%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$174,020 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$112,567
Medicare patients
141
Services billed
1,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate44$343,301
VraylarCariprazine Hcl133$214,640
RexultiBrexpiprazole54$79,522
TrintellixVortioxetine Hydrobromide88$48,511
NuplazidPimavanserin Tartrate11$44,327
AuvelityDextromethorphan Hbr/Bupropion25$43,569
Lurasidone Hcl48$31,850
LybalviOlanzapine/Samidorphan Malate13$19,932
VyvanseLisdexamfetamine Dimesylate19$7,290
Aripiprazole170$6,323
Lisdexamfetamine Dimesylate19$5,533
Quetiapine Fumarate ErQuetiapine Fumarate59$5,057
Bupropion XlBupropion Hcl231$4,993
Vilazodone Hcl27$4,198
Olanzapine147$2,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$13$343,30144 claims
AbbVieVraylar$171,994$214,640133 claims
Otsuka America Pharmaceutical, Inc.Rexulti$187$79,52254 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$59$55,801107 claims
Axsome Therapeutics, Inc.Auvelity$27$43,56925 claims
Alkermes, Inc.Lybalvi$142$19,93213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Lodi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →